Greater efforts are needed to diversify the pharmaceutical supply chain to help proactively respond to and mitigate future crises, based on lessons learned from the coronavirus pandemic, according to the US Association for Accessible Medicines.
The AAM acknowledged that at this point in the coronavirus pandemic Americans have not experienced COVID-19 related drug shortages, adding...





